

Chapter 221

Topical Immunomodulators

Edward M. Esparza & Robert Sidbury

REFERENCES

1. Baine I, Abe BT, Macian F: Regulation of T-cell tolerance by calcium/NFAT signaling. *Immunol Rev* **231**:225, 2009
2. Ruzicka T, Assmann T, Homey B: Tacrolimus: The drug for the turn of the millennium? *Arch Dermatol* **135**:574, 1999
3. Hanifin JM et al: Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. *J Am Acad Dermatol* **53**:S186, 2005
4. Saripalli YV, Gadzia JE, Belsito DV: Tacrolimus ointment 0.1% in the treatment of nickel-induced allergic contact dermatitis. *J Am Acad Dermatol* **49**:477, 2003
5. Pascual JC, Fleisher AB: Tacrolimus ointment (protopic) for atopic dermatitis. *Skin Therapy Lett* **10**:1, 2004
6. Koo JY et al: Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: Results in 8000 patients. *J Am Acad Dermatol* **53**:S195, 2005
7. Shainhouse T, Eichenfield LF: Long-term safety of tacrolimus ointment in children treated for atopic dermatitis. *Expert Opin Drug Saf* **2**:457, 2003
8. Paller AS: Use of nonsteroidal topical immunomodulators for the treatment of atopic dermatitis in the pediatric population. *J Pediatr* **138**:163, 2001
9. Milingou M et al: Alcohol intolerance and facial flushing in patients treated with topical tacrolimus. *Arch Dermatol* **140**:1542, 2004
10. Antille C, Saurat JH, Lubbe J: Induction of rosaceaiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment. *Arch Dermatol* **140**:457, 2004
11. Bakos L, Bakos RM: Focal acne during topical tacrolimus therapy for vitiligo. *Arch Dermatol* **143**:1223, 2007
12. El Sayed F, et al: Rosaceaiform eruption to pimecrolimus. *J Am Acad Dermatol* **54**:548, 2006
13. Arellano FM et al: Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. *J Invest Dermatol* **127**:808, 2007
14. Berger TG et al: The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. *J Am Acad Dermatol* **54**:818, 2006
15. Fonacier L et al: Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. *J Allergy Clin Immunol* **115**:1249, 2005
16. Qureshi AA, Fischer MA: Topical calcineurin inhibitors for atopic dermatitis: Balancing clinical benefit and possible risks. *Arch Dermatol* **142**:633, 2006
17. Hickey JR et al: Does topical tacrolimus induce lentiginos in children with atopic dermatitis? A report of three cases. *Br J Dermatol* **152**:152, 2005
18. Mikhail M et al: Rapid enlargement of a malignant melanoma in a child with vitiligo vulgaris after application of topical tacrolimus. *Arch Dermatol* **144**:560, 2008
19. Wolff K: Pimecrolimus 1% cream for the treatment of atopic dermatitis. *Skin Therapy Lett* **10**:1, 2005
20. Wahn U et al: Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. *Pediatrics* **110**:e2, 2002
21. Chang YC et al: Current and potential uses of imiquimod. *South Med J* **98**:914, 2005
22. Sapijaszko MJ: Imiquimod 5% cream (Aldara) in the treatment of basal cell carcinoma. *Skin Therapy Lett* **10**:2, 2005
23. Schiller M et al: Immune response modifiers—Mode of action. *Exp Dermatol* **15**:331, 2006
24. Schon MP, Schon M, Klotz KN: The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. *J Invest Dermatol* **126**:1338, 2006
25. Edwards L, Ferenczy A, Eron L, et al: Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. *Arch Dermatol* **134**:25, 1998

26. Marks R et al: Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: Results of a multicenter 6-week dose-response trial. *J Am Acad Dermatol* **44**:807, 2001
27. Geisse J et al: Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from two phase III, randomized, vehicle-controlled studies. *J Am Acad Dermatol* **50**:722, 2004
28. Love WE, Bernhard JD, Bordeaux JS: Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: A systematic review. *Arch Dermatol* **145**:1431, 2009
29. Hadley G, Derry S, Moore RA: Imiquimod for actinic keratosis: Systematic review and meta-analysis. *J Invest Dermatol* **126**:1251, 2006
30. Swanson N et al: Optimizing imiquimod for treating actinic keratoses of the full face or balding scalp: Imiquimod 2.5% and 3.75% applied daily for two 2-week cycles. *Montana Academy of Dermatology Annual Meeting Big Sky, MT*, 2010
31. Li VW et al: Imiquimod as an antiangiogenic agent. *J Drugs Dermatol* **4**:708, 2005
32. Sidbury R et al: Topically applied imiquimod inhibits vascular tumor growth in vivo. *J Invest Dermatol* **121**:1205, 2003
33. Gencoglan G, Inanir I, Gunduz K: Pyogenic granuloma in two children successfully treated with imiquimod 5% cream. *Pediatr Dermatol* **26**:366, 2009
34. Martinez MI et al: Infantile hemangioma: Clinical resolution with 5% imiquimod cream. *Arch Dermatol* **138**:881, 2002
35. Tritton SM et al: Pyogenic granuloma in ten children treated with topical imiquimod. *Pediatr Dermatol* **26**:269, 2009
36. Welsh O et al: Treatment of infantile hemangiomas with short-term application of imiquimod 5% cream. *J Am Acad Dermatol* **51**:639, 2004
37. McCuaig CC et al: A phase II, open-label study of the efficacy and safety of imiquimod in the treatment of superficial and mixed infantile hemangioma. *Pediatr Dermatol* **26**:203, 2009
38. Al-Mutairi N et al: Comparative study on the efficacy, safety, and acceptability of imiquimod 5% cream versus cryotherapy for molluscum contagiosum in children. *Pediatr Dermatol*, **27**(4):388-394, 2009
39. Badavanis G et al: Successful treatment of granuloma annulare with imiquimod cream 5%: a report of four cases. *Acta Derm Venereol* **85**:547, 2005
40. Stephenson S, Nedorost S: Granuloma annulare: dramatically altered appearance after application of 5% imiquimod cream. *Pediatr Dermatol* **25**:138, 2008
41. Agarwal S, Berth-Jones J: Porokeratosis of Mibelli: Successful treatment with 5% imiquimod cream. *Br J Dermatol* **146**:338, 2002
42. Berman B et al: Double-blind, randomized, placebo-controlled, prospective study evaluating the tolerability and effectiveness of imiquimod applied to postsurgical excisions on scar cosmesis. *Dermatol Surg* **31**:1399, 2005
43. Dusza SW et al: Treatment of dysplastic nevi with 5% imiquimod cream, a pilot study. *J Drugs Dermatol* **5**:56, 2006
44. Erba gci Z, Erba gci I, Almila Tuncel A: Rapid improvement of human orf (ecthyma contagiosum) with topical imiquimod cream: report of four complicated cases. *J Dermatolog Treat* **16**:353, 2005
45. Hughes PS: Treatment of lymphomatoid papulosis with imiquimod 5% cream. *J Am Acad Dermatol* **54**:546, 2006
46. Le T et al: Preliminary results of 5% imiquimod cream in the primary treatment of vulva intraepithelial neoplasia grade 2/3. *Am J Obstet Gynecol* **194**:377, 2006
47. Zampogna JC et al: Treatment of primary limited cutaneous extramammary Paget's disease with topical imiquimod monotherapy: Two case reports. *J Am Acad Dermatol* **47**:S229, 2002
48. Allen A et al: Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. *Arch Dermatol* **137**:747, 2001
49. Lakhanpaul M et al: Low systemic exposure in infants with atopic dermatitis in a 1-year pharmacokinetic study with pimecrolimus cream 1%*. *Exp Dermatol* **15**:138, 2006
50. Sauder DN: Immunomodulatory and pharmacologic properties of imiquimod. *J Am Acad Dermatol* **43**:S6, 2000
51. Ashcroft DM et al: Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: Meta-analysis of randomised controlled trials. *BMJ* **330**:516, 2005
52. Breneman D et al: Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: A randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle. *J Am Acad Dermatol* **58**:990-999, 2008

53. Paller AS et al: Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: Results from 3 randomized, comparative studies. *J Am Acad Dermatol* 52:810, 2005

